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AbstrAct
Single-agent poly (ADP-ribose) polymerase (PARP) 
inhibitors (PARPi) have been approved as the first targeted 
therapy available for patients with BRCA-mutated HER2-
negative metastatic breast cancer. This meta-analysis 
aimed to better evaluate activity, efficacy and safety of 
single-agent PARPi in this population. A systematic search 
of Medline, Embase and conference proceedings up to 
31 January 2018 was conducted to identify randomised 
controlled trials (RCTs) investigating single-agent PARPi 
versus monochemotherapy in patients with BRCA-
mutated HER2-negative metastatic breast cancer. Using 
the random-effect model, we calculated summary risk 
estimates (pooled HR and OR with 95% CI) for progression-
free survival (PFS), overall survival (OS), objective response 
rate (ORR), any grade and grade 3–4 adverse events (AEs), 
treatment discontinuation rate and time to deterioration 
in quality of life (QoL). Two RCTs (n=733) were included. 
As compared with monochemotherapy, single-agent 
PARPi significantly improved PFS (HR 0.56(95% CI 0.45 to 
0.70)) and ORR (OR 4.15 (95% CI 2.82 to 6.10)), with no 
difference in OS (HR 0.82 (95% CI 0.64 to 1.05)). Single-
agent PARPi significantly increased risk of anaemia and 
any grade headache, but reduced risk of neutropenia and 
any grade palmar-plantar erythrodysesthesia syndrome 
as compared with monochemotherapy. No significant 
differences in other AEs and treatment discontinuation rate 
were observed. Patients treated with PARPi experienced 
a significant delayed time to QoL deterioration (HR 0.40 
(95% CI 0.29 to 0.54)). Single-agent PARPi showed to 
be an effective, well tolerated and useful treatment in 
maintaining QoL of patients with BRCA-mutated HER2-
negative metastatic breast cancer.
BaCkground
Among unselected patients with breast cancer, 
approximately 10% harbour a germ line 
mutation in BRCA1 or BRCA2 genes.1 These 
are tumour suppressor genes mainly involved 
in the maintenance of genome integrity using 
one of the major DNA damage repair path-
ways named homologous recombination.2 
Poly (ADP-ribose) polymerase (PARP) is a 
family of nuclear enzymes with a key role in 
the recognition and repair of DNA single-
strand breaks.3 In the presence of PARP 
inhibitors (PARPi), the PARP-dependent 
DNA repair system cannot be activated with 
consequent development of double-strand 
breaks. In normal cells, these breakages can 
be repaired through the homologous recom-
bination pathways with subsequent retrieval 
of DNA integrity and cell survival. Conversely, 
in BRCA-mutated cells, homologous recombi-
nation is defective and these damages cannot 
be efficiently repaired resulting in cell deaths 
(ie, the concept of synthetic lethality).4 5 
Preclinical studies showed that BRCA1/2-de-
ficient cancer cells are sensitive to PARP inhi-
bition, mostly due to the persistence of DNA 
lesions that would be ordinarily repaired by 
the homologous recombination pathway.6 
Based on this strong biological rationale, the 
study by Tutt and colleagues then provided 
the proof of concept for the potential clin-
ical utility of single-agent PARPi in patients 
with BRCA-mutated metastatic breast cancer.7 
Following these results, over the past years, 
several clinical trials have evaluated and are 
currently investigating the role of different 
PARPi in this population.
Recently, based on the results of the phase 
III randomised controlled trial (RCT) Olym-
piAD,8 single-agent PARPi olaparib has 
been approved as the first targeted therapy 
available for patients with BRCA-mutated 
HER2-negative metastatic breast cancer.9 
Therefore, currently, these patients are 
candidates to receive PARPi in the course 
of their metastatic disease. Hence, it would 
be important to have a clear overview on 
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potential harms and benefits with the use of these drugs 
in terms of expected clinical outcomes, risk of developing 
adverse events (AEs) and impact on quality of life (QoL). 
We performed a systematic review and meta-analysis to 
better elucidate the role of single-agent PARPi for the 
treatment of patients with BRCA-mutated HER2-negative 
metastatic breast cancer.
Material and Methods
The present study was a quantitative synthesis of RCTs 
aiming to assess the activity, efficacy and safety of 
single-agent PARPi (PARPi group) as compared with 
standard monochemotherapy (chemotherapy group) in 
patients with BRCA-mutated HER2-negative metastatic 
breast cancer.
data sources and strategy
Eligible studies were identified by a systematic litera-
ture search of Medline and Embase databases, without 
language or date restriction up to 31 January 2018. 
Additionally, relevant reports of unpublished studies 
were identified through the proceedings of the annual 
meetings of the European Society for Medical Oncology, 
the American Society of Clinical Oncology and the San 
Antonio Breast Cancer Symposium. Finally, references of 
retrieved papers addressing the topic of PARPi in breast 
cancer were examined to identify additional relevant 
studies.
The Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses guidelines were followed.10
article selection and data extraction
Eligible trials had to satisfy the following criteria: (A) phase 
II or III RCTs with published or presented results; (B) 
RCTs including patients with BRCA-mutated HER2-neg-
ative metastatic breast cancer treated with single-agent 
PARPi in the experimental arm and monochemotherapy 
in the control arm; (C) studies with available data on 
progression-free survival (PFS) and/or overall survival 
(OS) and/or objective response rate (ORR) and/or AEs 
and/or QoL; (D) studies with sufficient data to estimate 
HR or OR and 95% CI for the study end points in the two 
groups of interest (PARPi vs chemotherapy group).
The following studies were excluded from the present 
meta-analysis: (A) non-RCTs evaluating the role of PARPi 
in patients with BRCA-mutated HER2-negative metastatic 
breast cancer; (B) RCTs in which PARPi were combined 
with other anticancer agents in the experimental arm; 
(C) ongoing studies without available and/or sufficient 
data at the moment of the literature search.
data extraction
The following variables were extracted independently by 
two authors (FP and ML) from the selected studies: name 
of the trial, year of publication, sample size and source 
of study subjects (experimental and control arms), type 
of PARPi used in the experimental arm, type of chemo-
therapy in the control arm, hormone receptor status, 
and number of patients previously treated with plati-
num-based chemotherapy. Furthermore, for the purpose 
of our planned analyses, study-specific rates of PFS, 
OS, ORR, AEs (of any grade and grade 3–4), treatment 
discontinuation due to AEs and time to deterioration in 
QoL were collected.
study objectives
The objectives of the present meta-analysis were to 
compare the activity, efficacy and safety between the 
PARPi group and the chemotherapy group.
The activity and efficacy end points were PFS, OS and 
ORR in the overall population. Exploratory subgroup 
analyses of PFS investigated if treatment activity differed 
according to hormone receptor status (hormone recep-
tor-positive cohort vs hormone receptor-negative cohort) 
or to prior exposure to platinum-based chemotherapy 
(prior platinum cohort vs no prior platinum cohort).
In terms of safety profile, the following AEs were consid-
ered: overall incidence of any grade AEs, overall inci-
dence of grade 3–4 AEs, neutropenia and anaemia of any 
grade and grade 3–4, as well as fatigue, nausea, vomiting, 
headache, diarrhoea and palmar-plantar erythrodyses-
thesia of any grade. Furthermore, we investigated the rate 
of treatment discontinuation following AEs and the time 
to deterioration in QoL.
statistical analysis
HR and 95% CI were calculated for PFS, OS and the time 
to deterioration in QoL. HR <1 indicates lower proba-
bility of developing EFS and OS events and delayed dete-
rioration in QoL in the PARPi group. OR and 95% CI 
were calculated for the effect for ORR, AEs and treatment 
discontinuation. OR >1 indicates higher ORR, AEs and 
treatment discontinuation rates in the PARPi group.
The pooled estimates of HR and OR were calculated by 
means of DerSimonian and Laird random-effects model 
method.11 Higgins I2 index was obtained to measure the 
degree of heterogeneity of the results.12
All reported p values were considered statistically 
significant if <0.05 (two-sided). Statistical analyses were 
performed and forest plots were drawn with STATA soft-
ware V.13.1 (StataCorp, College Station, Texas, USA).
results
study selection
The literature search returned 183 entries: after applying 
all the eligibility criteria, two RCTs (the OlympiAD 
and EMBRACA studies) were included in the present 
meta-analysis (figure 1).8 13
A total of 733 patients was included, of whom 492 
received single-agent PARPi (olaparib in the OlympiAD 
Trial and talazoparib in the EMBRACA Trial) and 241 
physician’s choice monochemotherapy (ie, capecitabine, 
eribulin, gemcitabine or vinorelbine).
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Table 1 displays the main characteristics of the 
included studies. In both trials, about half of the 
patients had triple-negative breast cancer (TNBC); 
around 20%–25% of the included patients were previ-
ously treated with platinum-based chemotherapy (a 
previous platinum-based regimen was allowed if at least 
12 months occurred since the last dose in the neoadju-
vant or adjuvant settings, or if there was no evidence of 
disease progression during the treatment for the meta-
static disease).
Progression-free survival
PFS was the primary end point in both studies. In 
the OlympiAD and the EMBRACA trials, respectively, 
median PFS was 7.0 months and 8.6 months in the 
PARPi group versus 4.2 months and 5.6 months in the 
chemotherapy group.
By pooling the results of the two studies, single-agent 
PARPi was associated with a significantly improved PFS 
(HR 0.56 (95% CI 0.45 to 0.70, p<0.001)). No signif-
icant heterogeneity was observed (I2=0%, p=0.756; 
figure 2A).
In the subgroup analysis according to hormone 
receptor status, single-agent PARPi was associated with 
improved PFS reaching statistical significance only in 
the hormone receptor-negative cohort (HR 0.51 (95% 
CI 0.37 to 0.71, p<0.001)) (I2=31.5%, p=0.227; figure 3A 
and not in the hormone receptor-positive cohort 
Figure 1 The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart summarising the 
process for the identification of eligible studies. ASCO, American Society of Clinical Oncology; ESMO, European Society for 
Medical Oncology; SABCS, San Antonio Breast Cancer Symposium; PARPi, PARP inhibitor; RCT, randomised controlled trial.
Table 1 Randomised trials comparing single-agent PARPi to monochemotherapy in patients with BRCA-mutated HER2-
negative metastatic breast cancer
Study name 
















302 (205/97) 103 (50.2)/49 (50.5) 102 (49.8)/48 (49.5) 60 (29.3)/26 (26.8)
EMBRACA 
(2017)13




431 (287/144) 157 (54.7)/84 (58.3) 130 (45.3)/60 (41.7) 46 (16.0)/30 (21.0)
*Eribulin, capecitabine or vinorelbine (according to physician’s choice).
†Eribulin, capecitabine, gemcitabine or vinorelbine (according to physician’s choice).
CT, chemotherapy; HR+, hormone receptor-positive; HR−, hormone receptor-negative; PARPi, PARP inhibitor.
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(HR 0.62 (95% CI 0.36 to 1.07, p=0.085)) (I2=72.2%, 
p=0.058; figure 3B.
In the subgroup analysis according to prior exposure 
to platinum-based chemotherapy, the improvement in 
PFS with PARPi reached the statistical significance only 
in the no prior platinum cohort (HR 0.55 (95% CI 0.44 
to 0.69, p<0.001)) (I2=0.0%, p=0.532; figure 3C) and 
not in the prior platinum cohort (HR 0.70 (95% CI 0.47 
to 1.05, p=0.085)) (I2=0.0%, p=0.764; figure 3D.
overall survival
In the OlympiAD and the EMBRACA trials, respectively, 
median OS was 19.3 months and 22.3 months in the PARPi 
group versus 19.6 months and 19.5 months in the chemo-
therapy group.
The meta-analysis of the two trials did not show any 
significant difference in OS between the two groups 
(HR 0.82 (95% CI 0.64 to 1.05, p=0.120)) (I2=0%, 
p=0.501; figure 2B.
objective response rate
ORR was defined as complete response plus partial 
response and evaluated according to RECIST criteria V.1.1 
in both trials. A total of 233 (77.1%) of the 302 patients in 
the OlympiAD trial, and 333 (77.3%) of the 431 patients 
of the EMBRACA trial had measurable disease and were 
included in the response analysis.
ORR was 61.4% (237 of 386) in the PARPi group and 27.8% 
(50 of 180) in the chemotherapy group (OR 4.15 (95% CI 
2.82 to 6.10, p<0.001)) (I2=0.0%, p=0.634) (figure 4).
Figure 2 (A) Progression-free survival in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi 
versus those treated with monochemotherapy (controls). The size of the squares is proportional to the weight of each study. 
(B) Overall survival in  patients with  BRCA-mutated HER2-negative breast cancer  treated with PARPi versu s those treated 
with monochemotherapy (controls).1 The size of the squares is proportional to the weight of each study. PARPi, PARP inhibitor.
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Figure 3 (A) Progression-free survival in the hormone receptor-negative cohort patients treated with PARPi versus 
those treated with mono chemotherapy (controls). The size of the squares is proportional to the weight of each study. (B) 
Progression-free survival in the hormone receptor-positive cohort of patients treated with PARPi versus those treated with 
mono chemotherapy (controls). The size of the squares is proportional to the weight of each study. (C) Progression-free 
survival in the no prior platinum cohort of patients treated with PARPi versus those treated with mono chemotherapy (controls). 
The size of the squares is proportional to the weight of each study. (D) Progression-free survival in  the prior platinum cohort of 
patients treated with PARPi versus those treated with mono chemotherapy (controls). The size of the squares is proportional to 
the weight of each study. PARPi, PARP inhibitor. 
Figure 4 Objective response rate in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus 
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adverse events of any grade
Figure 5A summarises the comparative safety profile in 
terms of AEs of any grade in the PARPi group versus 
chemotherapy group. Overall, 481 of 491 patients (98.0%) 
in the PARPi group and 211 of 217 (97.2%) in the chemo-
therapy group presented AEs of any grade (OR 1.37 (95% 
CI 0.49 to 3.85, p=0.546)) (I2=0.0%, p=0.691).
Neutropenia
Neutropenia of any grade was reported in 155 of 491 
patients (31.6%) in the PARPi group and in 99 of 217 
(45.6%) in the chemotherapy group (OR 0.53 (95% CI 
0.29 to 0.96, p=0.036)) (I2=68.6%, p=0.075).
Anaemia
Anaemia of any grade was reported in 233 of 491 patients 
(47.5%) in the PARPi group and 47 of 217 (21.7%) in 
the chemotherapy group (OR 3.07, 95% CI 1.16 to 8.10, 
p=0.024)) (I2=85.3%, p=0.009).
Fatigue
Fatigue of any grade was reported in 203 of 491 patients 
(41.3%) in the PARPi group and 75 of 217 (34.6%) in 
the chemotherapy group (OR 1.35 (95% CI 0.96 to 1.90, 
p=0.083)) (I2=0.0%, p=0.992).
Nausea
Nausea of any grade was reported in 258 of 491 patients 
(52.5%) in the PARPi group and 91 of 217 (41.9%) in 
the chemotherapy group (OR 1.63 (95% CI 0.70 to 3.81, 
p=0.256)) (I2=84.8%, p=0.010).
Vomiting
Vomiting of any grade was reported in 132 of 491 patients 
(26.9%) in the PARPi group and 43 of 217 (19.8%) in 
the chemotherapy group (OR 1.56 (95% CI 0.75 to 3.23, 
p=0.234)) (I2=69.3%, p=0.071).
Decreased appetite
Decreased appetite of any grade was reported in 94 of 
491 patients (19.1%) in the PARPi group and 39 of 217 
(18.0%) in the chemotherapy group (OR 1.08 (95% CI 
0.71 to 1.63, p=0.734)) (I2=0.0%, p=0.396).
Headache
Headache of any grade was reported in 134 of 491 patients 
(27.3%) in the PARPi group and 42 of 217 (19.4%) in 
Figure 5 (A) Safety profile overview. Any grade neutropenia, any grade anaemia, any grade fatigue, any grade nausea, 
any grade vomiting, any grade decreased appetite, any grade headache, any grade diarrhoea and any grade palmar-
plantar erythrodysesthesia in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those 
treated with monochemotherapy (controls). (B) Safety profile overview. Grade 3–4 neutropenia and grade 3–4 anaemia in 
BRCA-mutated HER2-negative patients treated with PARPi versus those treated with monochemotherapy (controls). (C) 
Treatment discontinuation rate in BRCA-mutated HER2-negative patients treated with PARPi versus those treated with 
monochemotherapy (controls). The size of the squares is proportional to the weight of each study. (D) Time to clinically 
meaningful deterioration in quality of life in patients with BRCA-mutated HER2-negative metastatic breast cancer treated with 
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the chemotherapy group (OR 1.57 (95% CI 1.06 to 2.33, 
p=0.024)) (I2=0.0, p=0.627).
Diarrhoea
Diarrhoea of any grade was reported in 105 of 491 patients 
(21.3%) in the PARPi group and 53 of 217 (24.4%) in 
the chemotherapy group (OR 0.84 (95% CI 0.58 to 1.23, 
p=0.369)) (I2=0.0, p=0.725).
Palmar-plantar erythrodysesthesia syndrome
Palmar-plantar erythrodysesthesia syndrome of any grade 
was reported in 5 of 491 patients (1.0%) in the PARPi 
group and 47 of 217 (21.7%) in the chemotherapy 
group (OR 0.04 (95% CI 0.02 to 0.10, p<0.001)) (I2=0.0, 
p=0.393).
grade 3–4 adverse events
Figure 5B summarises the comparative safety profile for 
grade 3–4 AEs in the PARPi group versus chemotherapy 
group. Overall, 148 of 491 (30.1%) patients in the PARPi 
group and 78 of 217 (35.9%) in the chemotherapy group 
presented any grade 3–4 AEs (OR 0.76 (95% CI 0.43 to 
1.33, p=0.336)) (I2=62.6%, p=0.102).
Neutropenia
Grade 3–4 neutropenia was reported in 79 of 491 patients 
(16.1%) in the PARPi group and 68 of 217 (31.3%) in 
the chemotherapy group (OR 0.40 (95% CI 0.23 to 0.67, 
p=0.001)) (I2=43.8%, p=0.182).
Anaemia
Grade 3–4 anaemia was reported in 145 of 491 patients 
(29.5%) in the PARPi group and 10 of 217 (4.6%) in the 
chemotherapy group (OR 7.69 (95% CI 2.55 to 23.19, 
p<0.001)) (I2=61.9%, p=0.105).
treatment discontinuation rate and time to deterioration in 
Qol
Overall, 32 of 491 patients (6.5%) in the PARPi group 
and 19 of 217 (8.8%) in the chemotherapy group discon-
tinued the treatment due to AEs (OR 0.72 (95% CI 0.40 
to 1.31, p=0.287)) (I2=0.0%, p=0.691) (figure 5C).
The 30-item EORTC QLQ-C30 (European Organisa-
tion for Research and Treatment of Cancer Quality of 
Life Questionnaire) Score was used to assess patients’ 
health-related QoL in both trials; an increase or decrease 
of at least 10 points was considered a clinically mean-
ingful variation.
In the OlympiAD and EMBRACA trials, respectively, 
the median time to a clinically meaningful deteriora-
tion in QoL was not reached and was 24.3 months in the 
PARPi group versus 15.3 months and 6.3 months in the 
chemotherapy group.
As compared with monochemotherapy, single-agent 
PARPi was associated with a significant delayed time to 
clinically meaningful deterioration in QoL (HR 0.40 
(95% CI 0.29 to 0.54, p<0.001)) (I2=0.0%, p=0.671) 
(figure 5D).
disCussion
This meta-analysis assessed the activity, efficacy and safety 
of single-agent PARPi in patients with BRCA-mutated 
HER2-negative metastatic breast cancer. In comparison 
to standard monochemotherapy, single-agent PARPi was 
associated with a significantly improved PFS and ORR and 
no difference in OS. Use of single-agent PARPi was associ-
ated with a significantly increased risk of anaemia and any 
grade headache, but a reduced risk of neutropenia and 
any grade palmar-plantar  erythrodysesthesia syndrome, 
as compared with monochemotherapy. Notably, use of 
single-agent PARPi significantly delayed time to clinically 
meaningful QoL deterioration.
Overall, treatment with single-agent PARPi showed 
significant activity over standard monochemotherapy by 
halving the probability of developing disease progres-
sion (HR 0.56 (95% CI 0.45 to 0.70, p<0.001)) and by 
inducing a fourfold increased chance of tumour response 
(OR 4.15 (95% CI 2.82 to 6.10, p<0.001)). The signifi-
cantly increased tumour shrinkage with single-agent 
PARPi suggests that this treatment can also be a feasible 
option in patients with visceral symptomatic or rapidly 
progressing disease. Although no significant benefit was 
observed in terms of OS, both trials were not powered to 
detect differences in this end point.
While the majority of women with mutated BRCA1 
are at risk of developing triple-negative breast cancer, 
tumours arising in those carrying a BRCA2 mutation 
more commonly express the hormone receptors.14 
Both patients were included in a similar proportion in 
the OlympiAD and EMBRACA trials. With an explor-
atory analysis assessing the activity of single-agent PARPi 
according to hormone receptor status, the improve-
ment in PFS reached statistical significance only for 
patients with TNBC (HR 0.51 (95% CI 0.37 to 0.71, 
p<0.001)) and not for those with hormone receptor-pos-
itive tumours (HR 0.62 (95% CI 0.36 to 1.07, p=0.085)). 
Therefore, given also the poor prognosis and the limited 
treatment options, the benefit derived from single-agent 
PARPi may be particularly relevant for the management 
of the TNBC population.
Importantly, it is still unclear which is the best 
sequencing of treatments for patients with BRCA-mutated 
HER2-negative metastatic breast cancer. According to 
recent guidelines, platinum-based chemotherapy is the 
preferred treatment option for these patients.15 16 Based 
on the TNT study results, among the 48 patients with 
BRCA-mutated (any hormone receptor and HER2 status) 
metastatic breast cancer, treatment with carboplatin 
significantly increased ORR (68% vs 33.3%, p=0.03) and 
PFS (6.8 months vs 4.4 months, p=0.002) as compared with 
docetaxel.17 Hence, a growing proportion of patients with 
newly diagnosed BRCA-mutated HER2-negative meta-
static breast cancer is expected to receive treatment with 
platinum agents. In the OlympiAD and EMBRACA trials, 
a total of 162 (22.1%) patients had prior exposure to 
platinum-based regimens. In the present meta-analysis 
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no significant difference in PFS between the PARPi 
and chemotherapy groups in the prior platinum cohort 
(HR 0.70 (95% CI 0.47 to 1.05, p=0.085)) was observed, 
while the benefit from the use of single-agent PARPi 
became clearer in the no prior platinum cohort (HR 0.55 
(95% CI 0.44 to 0.69, p<0.001)). Noteworthy, the compar-
ator arm in both the OlympiAD and EMBRACA trials was 
composed of a platinum-free regimen.
Recently, the phase II trial BROCADE showed that 
the addition of veliparib to carboplatin/paclitaxel was 
associated with a numerically although not statistically 
significantly increased PFS (14.1 months vs 12.3 months, 
HR 0.79 (95% CI 0.54 to 1.16, p=0.227)) and OS (28.3 
months vs 25.9 months, HR 0.75 (95% CI 0.5 to 1.12, 
p=0.156));18 as in the neoadjuvant setting, this combina-
tion does not seem to be a promising option.19 Similarly, 
patients receiving veliparib and temozolomide experi-
enced significantly lower PFS, OS and ORR as compared 
with those treated with carboplatin/paclitaxel, confirming 
the limited activity of temozolomide in metastatic breast 
cancer, even with the addition of a PARPi.18 20 Although 
the combination with chemotherapy does not seem to 
be a strategy of particular interest, it would be important 
to have a head-to head comparison between PARPi and 
the platinum-based regimen as well as to further investi-
gate the activity of PARPi in platinum-exposed patients in 
order to better clarify the optimal sequence of treatment 
in patients with BRCA-mutated HER2-negative metastatic 
breast cancer.
As recently shown in the phase I/II trial MEDIOLA, the 
combination of PARPi and immune checkpoint inhib-
itors appears to be a promising combination for these 
patients.21 These results, together with the enhanced 
immunogenicity of BRCA-mutated cancers, provide 
strong scientific rationale to further explore this strategy 
to potentiate the activity of PARPi.22 Results of several 
ongoing trials exploring this combination are awaited.
Our meta-analysis also provides an overview of the 
expected safety and tolerance of single-agent PARPi that 
can be of value to discuss treatment risk and benefit ratio 
with patients. Single-agent PARPi significantly reduced 
the risk of developing some of the most common side 
effects of chemotherapy such as neutropenia (OR 0.53 
(95% CI 0.29 to 0.96)) and any grade palmar-plantar 
erythrodysesthesia syndrome (OR 0.04 (95% CI 0.02 
to 0.10)); however, this treatment was associated with 
an increased risk of anaemia (OR 3.07 (95% CI 1.16 to 
8.10)) and any grade headache (OR 1.57 (95% CI 1.06 
to 2.33)). As shown in an exploratory analysis within the 
OlympiAD Study, the onset of anaemia during treatment 
with olaparib occurs early and rarely leads to treatment 
discontinuation. Unlike anaemia related to cytotoxic 
chemotherapy, it remains fairly constant throughout 
exposure to olaparib, not increasing transfusion require-
ments with time.23
Importantly, treatment with single-agent PARPi signifi-
cantly delayed time to clinically meaningful deterioration 
in QoL (HR 0.40 (95% CI 0.29 to 0.54)) as compared 
with monochemotherapy. In the last years, the evalua-
tion of QoL and the use of patient-reported outcomes 
(PROs) has been implemented in the trials conducted 
in the metastatic setting, where the maintenance of QoL 
is a crucial goal to be accomplished.24 The integration 
of PROs into routine care has recently demonstrated 
to also improve the survival outcomes of patients with 
metastatic cancer.25 This further highlights that, in addi-
tion to physician’s reporting, patient’s assessment of 
AEs severity provides additional important information 
to better estimate the overall risk and benefit ratio of a 
given anticancer treatment.26 The findings that single-
agent PARPi was well tolerated and also the delayed time 
to clinically meaningful QoL deterioration supports the 
prominent role of these oral agents in the management 
of patients with BRCA-mutated HER2-negative metastatic 
breast cancer; this also extends the time until chemo-
therapy is necessary.
Some limitations of the present meta-analysis should 
be acknowledged. Only two RCTs were included, and 
one was available only in abstract form. Moreover, this 
meta-analysis is based on abstracted data and not on indi-
vidual patient-level data. Nevertheless, we believe that all 
the analyses performed may help in giving a point esti-
mate on the role of single-agent PARPi in the manage-
ment of patients with BRCA-mutated HER2-negative 
metastatic breast cancer.
In conclusion, single-agent PARPi showed to be an effec-
tive, well tolerated and useful treatment in maintaining 
QoL of patients with BRCA-mutated HER2-negative meta-
static breast cancer. Although the optimal sequence as 
well as the possible combination strategies are not still 
determined, this treatment can now be regarded as a clin-
ically relevant additional option in the therapeutic arma-
mentarium of these patients.
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